Natera, Inc. Q3 2025 Earnings Recap

NTRA Q3 2025 November 7, 2025

Natera reported robust Q3 2025 results, with revenue growth of 35% year-over-year driven by strong demand for its clinical products, particularly Signatera, alongside a notable improvement in gross margins.

Earnings Per Share Miss

$-0.64 vs $-0.39 est.

-65.9% surprise

Revenue Beat

592183000 vs 513454861 est.

+15.3% surprise

Market Reaction

1-Day +0.55%

5-Day +5.55%

30-Day +19.23%

Key Takeaways

Revenue for the quarter reached $592 million, significantly exceeding last year’s performance.
Clinical MRD tests exceeded 202,000, marking record growth with 21,500 additional units.
Gross margins surged to 64.9%, reflecting efficiency gains and cost management.
The company raised its 2025 revenue guidance by $160 million, now forecasting $2.18–$2.26 billion.
Expanding the product offering with the new Fetal Focus test, targeting over 20 genes with positive initial feedback.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NTRA on AllInvestView.